Illumina's EBIT per Share for the
three
months ended in Mar. 2026 was CHF0.93.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was CHF6.01.
During the past 12 months, the average EBIT per Share Growth Rate of Illumina was 3.40% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 32.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Illumina's EBIT per Share or its related term are showing as below:
XSWX:ILMN'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -30.1 Med: 28.55 Max: 313.7
Current: 32.4
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Illumina was 313.70% per year. The lowest was -30.10% per year. And the median was 28.55% per year.
XSWX:ILMN's 3-Year EBIT Growth Rate is ranked better than 72.19% of 169
companies
in the Medical Diagnostics & Research industry
Industry Median: 12.5
vs XSWX:ILMN: 32.40
Illumina's EBIT for the
three
months ended in Mar. 2026 was CHF143 Mil.
Illumina (XSWX:ILMN) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Illumina EBIT per Share Related Terms
Illumina EBIT per Share Historical Data
* Premium members only.
The historical data trend for Illumina's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF6.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Illumina (XSWX:ILMN) has a EBIT per Share of CHF6.01 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Illumina and its competitors. According to the industry distribution chart, Illumina ranks #47 out of 169 companies in the Medical Diagnostics & Research industry, placing it in the top 27.8%.
Is Illumina's EBIT per Share too high?
Illumina's current EBIT per Share is CHF6.01. Based on the distribution chart, Illumina ranks #47 out of 169 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Illumina has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Illumina's EBIT per Share compare to MTD and DGX?
According to the Medical Diagnostics & Research industry distribution chart, Illumina ranks #47 out of 169 companies for EBIT per Share. This puts Illumina in the upper half of its industry. The industry median EBIT per Share is 12.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 12.50, based on 169 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Illumina and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 12.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Illumina's current EBIT per Share is CHF6.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Illumina stock overvalued right now?
Illumina (XSWX:ILMN) has a current EBIT per Share of CHF6.01. The stock's GF Value™ is CHF105.51, compared to a current price of CHF143.95 — trading 36.4% above its estimated fair value. The current EBIT per Share is CHF6.01. Illumina's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Illumina (XSWX:ILMN), the current EBIT per Share is CHF6.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Illumina (XSWX:ILMN) Overvalued in 2026?
Based on GuruFocus' analysis, Illumina stock appears to be overvalued.
The current stock price of CHF143.95 is trading 36.4% above its estimated GF Value™ of CHF105.51.
Key valuation signals for XSWX:ILMN:
EBIT per Share: CHF6.01
GF Value™: CHF105.51 vs. price of CHF143.95 (36.4% above fair value)
No single metric tells the full story. See the XSWX:ILMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
76GF Score
Get the complete analysis for XSWX:ILMN
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ILMN has been successfully added to your 
